[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100416179":3},{"organization":4,"armGroups":7,"interventions":34,"overallOfficials":56,"centralContacts":60,"locations":68,"responsibleParty":84,"collaborators":86,"id":131,"slug":132,"hasResults":133,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":10,"eligibilityCriteria":137,"healthyVolunteers":133,"sex":138,"minAge":139,"maxAge":10,"enrollmentInfo":140,"targetDuration":143,"studyType":144,"phases":10,"briefSummary":145,"conditions":146,"keywords":10,"overallStatus":70,"whyStopped":10,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":157},{"fullName":5,"class":6},"The Netherlands Cancer Institute","OTHER",[8,14,19,24,29],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort A",null,"MLS patients managed by surgery only",[13],"Procedure: Surgery",{"label":15,"type":10,"description":16,"interventionNames":17},"Cohort B","MLS patients receiving preoperative RT to a dose of 36 Gy (equivalent) followed by surgery",[13,18],"Radiation: Preoperative RT 36Gy",{"label":20,"type":10,"description":21,"interventionNames":22},"Cohort C","MLS patients receiving preoperative RT to a dose of 50 Gy (equivalent) followed by surgery",[13,23],"Radiation: Preoperative RT 50Gy",{"label":25,"type":10,"description":26,"interventionNames":27},"Cohort D","MLS patients receiving surgery followed by postoperative RT to a dose of 50-66 Gy (equivalent)",[13,28],"Radiation: Postoperative RT 50-66Gy",{"label":30,"type":10,"description":31,"interventionNames":32},"Cohort E","MLS patients with oligometastatic and\u002For oligoprogressive disease receiving definitive RT to a dose of 36Gy (equivalent)",[33],"Radiation: RT 36Gy",[35,39,44,48,52],{"type":36,"name":37,"description":37,"armGroupLabels":38,"otherNames":10},"PROCEDURE","Surgery",[9,15,20,25],{"type":40,"name":41,"description":42,"armGroupLabels":43,"otherNames":10},"RADIATION","Preoperative RT 36Gy","Preoperative radiotherapy to 36Gy (equivalent)",[15],{"type":40,"name":45,"description":46,"armGroupLabels":47,"otherNames":10},"Preoperative RT 50Gy","Preoperative radiotherapy to 50Gy (equivalent)",[20],{"type":40,"name":49,"description":50,"armGroupLabels":51,"otherNames":10},"Postoperative RT 50-66Gy","Postoperative radiotherapy to 50-66Gy (equivalent)",[25],{"type":40,"name":53,"description":54,"armGroupLabels":55,"otherNames":10},"RT 36Gy","Definitive radiotherapy to 36Gy (equivalent)",[30],[57],{"name":58,"affiliation":5,"role":59},"Rick Haas, MD\u002FPhD","PRINCIPAL_INVESTIGATOR",[61,65],{"name":58,"role":62,"phone":63,"phoneExt":10,"email":64},"CONTACT","+31 20 512 9111","r.haas@nki.nl",{"name":66,"role":62,"phone":63,"phoneExt":10,"email":67},"Jules Lansu, MD\u002FPhD","j.lansu@nki.nl",[69],{"facility":5,"status":70,"city":71,"state":10,"zip":72,"country":73,"countryCode":74,"cosmosGeoPoint":75,"geoPoint":80,"contacts":81},"RECRUITING","Amsterdam","1066CX","Netherlands","NL",{"type":76,"coordinates":77},"Point",[78,79],4.88969,52.37403,{"lat":79,"lon":78},[82,83],{"name":58,"role":62,"phone":10,"phoneExt":10,"email":10},{"name":66,"role":62,"phone":10,"phoneExt":10,"email":10},{"type":85,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[87,89,91,93,95,97,99,101,104,106,108,110,112,114,117,119,121,123,125,127,129],{"name":88,"class":6},"Radboud University Medical Center",{"name":90,"class":6},"Maastro Clinic, The Netherlands",{"name":92,"class":6},"University Medical Center Groningen",{"name":94,"class":6},"Leiden University Medical Center",{"name":96,"class":6},"Vienna General Hospital",{"name":98,"class":6},"M.D. Anderson Cancer Center",{"name":100,"class":6},"University Hospital, Antwerp",{"name":102,"class":103},"Universitetssykehus","UNKNOWN",{"name":105,"class":6},"Haukeland University Hospital",{"name":107,"class":6},"Universitäts-Frauenklinik Graz",{"name":109,"class":6},"University Hospital Heidelberg",{"name":111,"class":6},"Mayo Clinic",{"name":113,"class":6},"Aarhus University Hospital",{"name":115,"class":116},"National Cancer Center, Japan","OTHER_GOV",{"name":118,"class":6},"Princess Margaret Hospital, Canada",{"name":120,"class":6},"MOUNT SINAI HOSPITAL",{"name":122,"class":6},"University of Sydney",{"name":124,"class":103},"Institute for Cancer Research and treatment",{"name":126,"class":6},"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano",{"name":128,"class":6},"Institut Curie",{"name":130,"class":6},"Australia and New Zealand Sarcoma Association","100416179","international-prospective-registry-on-local-treatment-approaches-in-mls-100416179",false,"NCT04699292","International Prospective Registry on Local Treatment Approaches in MLS","International Prospective Registry on Local Treatment Approaches in Myxoid Liposarcomas","Inclusion Criteria:\n\n* Age \\> 18 years\n* Biopsy proven MLS, including the reciprocal chromosomal translocation t(12;16)(q13;p11)\n* ECOG PS 0-2\n* Written informed consent to share coded information in this international Registry\n\nExclusion Criteria:\n\n* Prior radiotherapy to the target area\n* Pregnancy","ALL","18 Years",{"count":141,"type":142},300,"ESTIMATED","5 Years","OBSERVATIONAL","To prospectively study commonly used local treatment approaches in Myxoid Liposarcoma (MLS)",[147],"Myxoid Liposarcoma","2022-08-29",{"date":150,"type":151},"2022-08-30","ACTUAL",{"date":153,"type":151},"2021-01-18",{"date":155,"type":142},"2031-01",{"name":5,"class":6},1]